Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response

Area of Science:

• Oncology
• Immunology
• Microbiology
• Genetics

Background:

• Advances in cancer genomics and immunotherapy offer new treatment avenues.
• Current cancer immunotherapies often fail against tumors with low mutational burden.
• Bacterial translocation, a leakage of gut bacteria into sterile compartments, is explored as a novel cancer treatment strategy.

Purpose of the Study:

• To propose a novel hypothesis for cancer treatment using engineered bacteria and bacterial translocation.
• To explore strategies for enhancing anti-tumor immune responses.
• To overcome challenges posed by low mutational burden tumors.

Main Methods:

• Engineering commensal or live-attenuated bacteria with nucleic acids encoding tumor neoantigens.
• Selecting neoantigens from individual tumor RNA sequencing data.
• Utilizing compounds to induce bacterial translocation and neoantigen release in cancer patients.

Main Results:

• Hypothetical induction of bacterial translocation to release neoantigens.
• Potential for systemic release of neoantigens within an inflammatory context.
• Envisioned activation of tumor-specific CD4 and CD8 T-cells.

Conclusions:

• Engineered bacteria and induced bacterial translocation present a promising, hypothetical strategy for cancer immunotherapy.
• This approach aims to enhance immune recognition and response against challenging tumors.
• Further research into neoantigen selection, bacterial engineering, and translocation methods is warranted.